Immunomodulation, Part V: Probiotics
ACCORDING TO 2003 CENTERS for Disease Control and Prevention statistics, bacterial sepsis of the newborn is the eighth leading cause of death among neonates of all races and both sexes in the U.S., with a mortality rate of 18.9 per 100,000 live births, and necrotizing enterocolitis (NEC) is the thirteenth leading cause of death, with a mortality rate of 9.9 per 100,000 live births.1 Because these entities present such a significant public health challenge, researchers have been exploring various modalities, including immunomodulation, to enhance the neonatal immune system. Generally, the immunomodulators studied work through indirect stimulation or augmentation of the immune system.
Document Type: Research Article
Publication date: January 1, 2007
- Neonatal Network is no longer available to subscribers on Ingenta Connect. Please go to http://connect.springerpub.com/content/sgrnn to access your online subscription to Neonatal Network.